BridgeBio presents new Phase 3 acoramidis ATTR-CM outcomes data at ESC-HF 2026

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00
  • BridgeBio flagged new Phase 3 ATTRibute-CM analyses for acoramidis in transthyretin amyloid cardiomyopathy, scheduled for presentation at ESC Heart Failure 2026 in Barcelona on May 9-12.
  • Results will be presented in the future, including a late-breaking oral session focused on how acoramidis affected disease progression signals and how that translated into patient outcomes.
  • Additional presentations are set to cover effects on worsening heart failure events, heart-failure health status, and biomarker trends, pointing to sustained clinical benefit versus placebo without detailing numerical readouts.
  • Program update comes as acoramidis is already marketed as Attruby in US, with Bayer holding exclusive European rights where it is sold as BEYONTTRA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040730PRIMZONEFULLFEED9711784) on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.